{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T23:35:47Z","timestamp":1783467347528,"version":"3.55.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,7,23]],"date-time":"2019-07-23T00:00:00Z","timestamp":1563840000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013076","name":"National Major Science and Technology Projects of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013076","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.ijid.2019.07.023","type":"journal-article","created":{"date-parts":[[2019,7,26]],"date-time":"2019-07-26T11:16:46Z","timestamp":1564139806000},"page":"8-12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Guides concerning tenofovir exposure via breastfeeding: A comparison of drug dosages by developmental stage"],"prefix":"10.1016","volume":"87","author":[{"given":"Xiaotong","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fujie","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2019.07.023_bib0005","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1128\/AAC.00514-10","article-title":"Concentrations of tenofovir and emtricitabine in breast milk of HIV-1-infected women in Abidjan, Cote d\u2019Ivoire, in the ANRS 12109 TEmAA Study, Step 2","volume":"55","author":"Benaboud","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2019.07.023_bib0010","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/hiv.12252","article-title":"Pharmacokinetics of tenofovir during pregnancy and postpartum","volume":"16","author":"Best","year":"2015","journal-title":"HIV Med"},{"key":"10.1016\/j.ijid.2019.07.023_bib0015","unstructured":"Centers for Disease Control and Prevention. https:\/\/www.cdc.gov\/breastfeeding\/breastfeeding-special-circumstances\/maternal-or-infant-illnesses\/hiv.html, [Accessed 10 June 2019]."},{"key":"10.1016\/j.ijid.2019.07.023_bib0020","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/S0736-0266(02)00074-8","article-title":"Tenofovir treatment at 30mg\/kg\/day can inhibit cortical bone mineralization in growing rhesus monkeys (Macaca mulatta)","volume":"20","author":"Castillo","year":"2002","journal-title":"J Orthop Res"},{"key":"10.1016\/j.ijid.2019.07.023_bib0025","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1097\/QAD.0b013e32835c208b","article-title":"The pharmacokinetics, safety and efficacy of tenofovir and emtricitabine in HIV-1-infected pregnant women","volume":"27","author":"Colbers","year":"2013","journal-title":"AIDS (London, England)"},{"key":"10.1016\/j.ijid.2019.07.023_bib0030","first-page":"1","article-title":"British HIV Association guidelines for the management of HIV infection in pregnant women 2012 (2014 interim review)","volume":"15 Suppl. 4","author":"de Ruiter","year":"2014","journal-title":"HIV Med"},{"key":"10.1016\/j.ijid.2019.07.023_bib0035","series-title":"EACS guidelines 2017","author":"(EACS) E.A.C.S","year":"2018"},{"key":"10.1016\/j.ijid.2019.07.023_bib0040","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"Electronic address e.e.e. and European Association for the Study of the L. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","author":"European Association for the Study of the Liver","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.ijid.2019.07.023_bib0045","doi-asserted-by":"crossref","first-page":"5914","DOI":"10.1128\/AAC.00544-11","article-title":"Pharmacokinetics and safety of single-dose tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant women and their infants","volume":"55","author":"Flynn","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2019.07.023_bib0050","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1097\/QAD.0000000000001145","article-title":"Effectiveness and safety of oral HIV preexposure prophylaxis for all populations","volume":"30","author":"Fonner","year":"2016","journal-title":"AIDS (London, England)"},{"key":"10.1016\/j.ijid.2019.07.023_bib0055","first-page":"1049","article-title":"Risk of hepatitis B transmission in breast-fed infants of chronic hepatitis B carriers","volume":"99","author":"Hill","year":"2002","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ijid.2019.07.023_bib0060","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/clpt.2008.201","article-title":"Population pharmacokinetics of tenofovir in HIV-1-infected pregnant women and their neonates (ANRS 12109)","volume":"85","author":"Hirt","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ijid.2019.07.023_bib0065","doi-asserted-by":"crossref","first-page":"297","DOI":"10.14218\/JCTH.2016.00019","article-title":"Guideline of prevention and treatment for chronic hepatitis B (2015 Update)","volume":"5","author":"Hou","year":"2017","journal-title":"J Clin Transl Hepatol"},{"key":"10.1016\/j.ijid.2019.07.023_bib0070","doi-asserted-by":"crossref","first-page":"e264","DOI":"10.1097\/INF.0000000000002152","article-title":"Tenofovir disoproxil fumarate use during pregnancy and infant bone health: the tenofovir in pregnancy pilot study","volume":"37","author":"Kourtis","year":"2018","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.ijid.2019.07.023_bib0075","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nrgastro.2016.196","article-title":"HBV in 2016: global and immunotherapeutic insights into hepatitis B","volume":"14","author":"Maini","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.ijid.2019.07.023_bib0080","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/QAI.0b013e3182a921eb","article-title":"Pharmacokinetics and safety of tenofovir in HIV-infected women during labor and their infants during the first week of life","volume":"65","author":"Mirochnick","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.ijid.2019.07.023_bib0085","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/QAD.0000000000001313","article-title":"Tenofovir disoproxil fumarate safety for women and their infants during pregnancy and breastfeeding","volume":"31","author":"Mofenson","year":"2017","journal-title":"Aids"},{"key":"10.1016\/j.ijid.2019.07.023_bib0090","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002132","article-title":"Pre-exposure prophylaxis use by breastfeeding HIV-uninfected women: a prospective short-term study of antiretroviral excretion in breast milk and infant absorption","volume":"13","author":"Mugwanya","year":"2016","journal-title":"PLoS Med"},{"key":"10.1016\/j.ijid.2019.07.023_bib0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/QAI.0000000000001359","article-title":"Safety of tenofovir disoproxil fumarate-based antiretroviral therapy regimens in pregnancy for HIV-infected women and their infants: a systematic review and meta-analysis","volume":"76","author":"Nachega","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.ijid.2019.07.023_bib0100","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1093\/jac\/dkv435","article-title":"Concentrations of tenofovir, lamivudine and efavirenz in mothers and children enrolled under the Option B-Plus approach in Malawi","volume":"71","author":"Palombi","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2019.07.023_bib0105","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciy982","article-title":"Maternal and infant bone mineral density 1 year after delivery in a randomized, controlled trial of maternal tenofovir disoproxil fumarate to prevent mother-to-child transmission of hepatitis B virus","author":"Salvadori","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2019.07.023_bib0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol Int"},{"key":"10.1016\/j.ijid.2019.07.023_bib0115","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1093\/cid\/civ437","article-title":"Lower newborn bone mineral content associated with maternal use of tenofovir disoproxil fumarate during pregnancy","volume":"61","author":"Siberry","year":"2015","journal-title":"Clinical Infect Dis"},{"key":"10.1016\/j.ijid.2019.07.023_bib0120","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatol (Baltimore, Md)"},{"key":"10.1016\/j.ijid.2019.07.023_bib0125","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/jac\/dkx507","article-title":"Plasma and breast milk pharmacokinetics of emtricitabine, tenofovir and lamivudine using dried blood and breast milk spots in nursing African mother-infant pairs","volume":"73","author":"Waitt","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2019.07.023_bib0130","unstructured":"World Health Organization, Breastfeeding. https:\/\/www.who.int\/topics\/breastfeeding\/en\/, [Accessed 10 June 2019]."},{"key":"10.1016\/j.ijid.2019.07.023_bib0135","series-title":"Guidelines for the prevention care and treatment of persons with chronic hepatitis B infection: Mar-15","author":"World Health Organization","year":"2015"},{"key":"10.1016\/j.ijid.2019.07.023_bib0140","series-title":"Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. nd, (ed.). Geneva","article-title":"Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach","author":"World Health Organization","year":"2016"},{"key":"10.1016\/j.ijid.2019.07.023_bib0145","series-title":"In Guideline: updates on HIV and infant feeding: the duration of breastfeeding, and support from health services to improve feeding practices among mothers living with HIV. Geneva","article-title":"Guideline: updates on HIV and infant feeding: the duration of breastfeeding, and support from health services to improve feeding practices among mothers living with HIV","author":"World Health Organization","year":"2016"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S120197121930308X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S120197121930308X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:45:29Z","timestamp":1761119129000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S120197121930308X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":29,"alternative-id":["S120197121930308X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2019.07.023","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Guides concerning tenofovir exposure via breastfeeding: A comparison of drug dosages by developmental stage","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2019.07.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}]}}